Global Nivolumab Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
Description
Summary
According to APO Research, The global Nivolumab market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Nivolumab is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Nivolumab is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Nivolumab is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Nivolumab is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Nivolumab include Ono Pharmaceutical and Bristol-Myers Squibb etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Nivolumab, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Nivolumab, also provides the sales of main regions and countries. Of the upcoming market potential for Nivolumab, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Nivolumab sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Nivolumab market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Nivolumab sales, projected growth trends, production technology, application and end-user industry.
Nivolumab Segment by Company
Ono Pharmaceutical
Bristol-Myers Squibb
Nivolumab Segment by Type
Injection 4mL
Injection 10mL
Nivolumab Segment by Application
Metastatic Squamous NSCLC
Metastatic Melanoma
Renal Cell Carcinoma
Classical Hodgkin Lymphoma
Unresectable Melanoma
Others
Nivolumab Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nivolumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nivolumab and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nivolumab.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Nivolumab market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nivolumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Nivolumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Nivolumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global Nivolumab market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Nivolumab is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Nivolumab is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Nivolumab is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Nivolumab is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Nivolumab include Ono Pharmaceutical and Bristol-Myers Squibb etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Nivolumab, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Nivolumab, also provides the sales of main regions and countries. Of the upcoming market potential for Nivolumab, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Nivolumab sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Nivolumab market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Nivolumab sales, projected growth trends, production technology, application and end-user industry.
Nivolumab Segment by Company
Ono Pharmaceutical
Bristol-Myers Squibb
Nivolumab Segment by Type
Injection 4mL
Injection 10mL
Nivolumab Segment by Application
Metastatic Squamous NSCLC
Metastatic Melanoma
Renal Cell Carcinoma
Classical Hodgkin Lymphoma
Unresectable Melanoma
Others
Nivolumab Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nivolumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nivolumab and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nivolumab.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Nivolumab market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nivolumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Nivolumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Nivolumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
172 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Nivolumab Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Nivolumab Market Size Estimates and Forecasts (2020-2031)
- 1.4 Global Nivolumab Sales Estimates and Forecasts (2020-2031)
- 1.5 Global Nivolumab Market Average Price (2020-2031)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 2 Global Nivolumab Market Dynamics
- 2.1 Nivolumab Industry Trends
- 2.2 Nivolumab Industry Drivers
- 2.3 Nivolumab Industry Opportunities and Challenges
- 2.4 Nivolumab Industry Restraints
- 3 Nivolumab Market by Manufacturers
- 3.1 Global Nivolumab Revenue by Manufacturers (2020-2025)
- 3.2 Global Nivolumab Sales by Manufacturers (2020-2025)
- 3.3 Global Nivolumab Average Sales Price by Manufacturers (2020-2025)
- 3.4 Global Nivolumab Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
- 3.5 Global Nivolumab Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Nivolumab Manufacturers, Product Type & Application
- 3.7 Global Nivolumab Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Nivolumab Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Nivolumab Players Market Share by Revenue in 2024
- 3.8.3 2024 Nivolumab Tier 1, Tier 2, and Tier 3
- 4 Nivolumab Market by Type
- 4.1 Nivolumab Type Introduction
- 4.1.1 Injection 4mL
- 4.1.2 Injection 10mL
- 4.2 Global Nivolumab Sales by Type
- 4.2.1 Global Nivolumab Sales by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Nivolumab Sales by Type (2020-2031)
- 4.2.3 Global Nivolumab Sales Market Share by Type (2020-2031)
- 4.3 Global Nivolumab Revenue by Type
- 4.3.1 Global Nivolumab Revenue by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Nivolumab Revenue by Type (2020-2031)
- 4.3.3 Global Nivolumab Revenue Market Share by Type (2020-2031)
- 5 Nivolumab Market by Application
- 5.1 Nivolumab Application Introduction
- 5.1.1 Metastatic Squamous NSCLC
- 5.1.2 Metastatic Melanoma
- 5.1.3 Renal Cell Carcinoma
- 5.1.4 Classical Hodgkin Lymphoma
- 5.1.5 Unresectable Melanoma
- 5.1.6 Others
- 5.2 Global Nivolumab Sales by Application
- 5.2.1 Global Nivolumab Sales by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Nivolumab Sales by Application (2020-2031)
- 5.2.3 Global Nivolumab Sales Market Share by Application (2020-2031)
- 5.3 Global Nivolumab Revenue by Application
- 5.3.1 Global Nivolumab Revenue by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Nivolumab Revenue by Application (2020-2031)
- 5.3.3 Global Nivolumab Revenue Market Share by Application (2020-2031)
- 6 Global Nivolumab Sales by Region
- 6.1 Global Nivolumab Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Nivolumab Sales by Region (2020-2031)
- 6.2.1 Global Nivolumab Sales by Region (2020-2025)
- 6.2.2 Global Nivolumab Sales Forecasted by Region (2025-2030)
- 6.3 North America
- 6.3.1 North America Nivolumab Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.3.2 North America Nivolumab Sales by Country (2020-2031)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Nivolumab Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.4.2 Europe Nivolumab Sales by Country (2020-2031)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Nivolumab Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.5.2 Asia Pacific Nivolumab Sales by Country (2020-2031)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Nivolumab Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.6.2 South America, Middle East and Africa Nivolumab Sales by Country (2020-2031)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
- 7 Global Nivolumab Revenue by Region
- 7.1 Global Nivolumab Revenue by Region
- 7.1.1 Global Nivolumab Revenue by Region: 2020 VS 2024 VS 2031
- 7.1.2 Global Nivolumab Revenue by Region (2020-2025)
- 7.1.3 Global Nivolumab Revenue by Region (2026-2031)
- 7.1.4 Global Nivolumab Revenue Market Share by Region (2020-2031)
- 7.2 North America
- 7.2.1 North America Nivolumab Revenue (2020-2031)
- 7.2.2 North America Nivolumab Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.3 Europe
- 7.3.1 Europe Nivolumab Revenue (2020-2031)
- 7.3.2 Europe Nivolumab Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Nivolumab Revenue (2020-2031)
- 7.4.2 Asia-Pacific Nivolumab Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Nivolumab Revenue (2020-2031)
- 7.5.2 South America, Middle East and Africa Nivolumab Revenue Share by Country: 2020 VS 2024 VS 2031
- 8 Company Profiles
- 8.1 Ono Pharmaceutical
- 8.1.1 Ono Pharmaceutical Comapny Information
- 8.1.2 Ono Pharmaceutical Business Overview
- 8.1.3 Ono Pharmaceutical Nivolumab Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.1.4 Ono Pharmaceutical Nivolumab Product Portfolio
- 8.1.5 Ono Pharmaceutical Recent Developments
- 8.2 Bristol-Myers Squibb
- 8.2.1 Bristol-Myers Squibb Comapny Information
- 8.2.2 Bristol-Myers Squibb Business Overview
- 8.2.3 Bristol-Myers Squibb Nivolumab Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.2.4 Bristol-Myers Squibb Nivolumab Product Portfolio
- 8.2.5 Bristol-Myers Squibb Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Nivolumab Value Chain Analysis
- 9.1.1 Nivolumab Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Nivolumab Production Mode & Process
- 9.2 Nivolumab Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Nivolumab Distributors
- 9.2.3 Nivolumab Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

